EyeGene Inc.
Financials
Valuation Metrics
EyeGene Inc.'s Market Cap is ₩750B. At end of 2025 it was ₩752B. Ranked #1393 of 2,410 in KR market (top 58%), #782 of 1,631 on KOSDAQ (top 48%), #152 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 66%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 75.00B KRW | KR#1,393/2,410 Sec#152/231 |
| Revenue | 4.48B KRW | KR#2,337/2,410 Sec#199/231 |
| Net Income | -21.03B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 68.05B KRW | KR#2,029/2,410 Sec#171/231 |
| Net Assets | 54.25B KRW | KR#1,855/2,410 Sec#157/231 |
| Employees | 50 | KR#2,041/2,410 Sec#189/231 |
| Value | ||
| P/B | 1.38x | KR#1,782/2,410 Sec#125/231 |
| P/S | 16.73x | KR#2,325/2,410 Sec#184/231 |
| FCF Yield | -8.11% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -38.76% | KR#2,229/2,410 Sec#188/231 |
| ROA | -30.90% | KR#2,312/2,410 Sec#202/231 |
| Op. Margin | -276.19% | KR#2,333/2,410 Sec#192/231 |
| Revenue Growth | 13.04% | KR#757/2,410 Sec#72/231 |
| Financial Health | ||
| Debt Ratio | 25.43% | KR#487/2,410 Sec#58/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | -6.08B KRW | KR#1,549/2,410 Sec#125/231 |
| Cash | 10.19B KRW | KR#1,677/2,410 Sec#143/231 |
| Current Ratio | 3.97x | KR#389/2,410 Sec#60/231 |
| Performance | ||
| 1Y Return | -6.27% | KR#693/2,410 Sec#38/231 |
| 1M Return | -9.54% | KR#1,249/2,410 Sec#128/231 |
| From 52W High | -38.15% | KR#667/2,410 Sec#43/231 |
| 1Y MDD | -49.77% | KR#946/2,410 Sec#75/231 |
| Trading | ||
| Volume | 35,689 shares | KR#1,311/2,410 Sec#132/231 |
| Trading Value | 61.3M KRW | KR#1,749/2,410 Sec#186/231 |
| Foreign Own. | 1.71% | KR#1,743/2,410 Sec#168/231 |
| Per Share | ||
| EPS | -486 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,255 KRW | KR#2,249/2,410 Sec#203/231 |
Company Info
Eyegene, a bio venture founded in 2000 for proteomics and immunology research, established mRNA subsidiary Renaim and operates EyeGene Australia in 2021. The company's core focus is developing mRNA vaccines and AAV gene therapies, with gene and cell therapies at its center, having completed Phase 1/2a clinical trials for a COVID-19 preventive vaccine. It collaborates with five domestic and international companies on next-generation mRNA vaccine development and prioritizes technology acquisition through revenue-generating business and venture enterprise investments. Eyegene is headquartered in Uiwang-si, Gyeonggi-do.